Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (75) 75
female (60) 60
male (58) 58
middle aged (55) 55
aged (54) 54
adult (48) 48
lung neoplasms - drug therapy (45) 45
carcinoma, non-small-cell lung - drug therapy (40) 40
oncology (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
index medicus (35) 35
treatment outcome (23) 23
lung neoplasms - mortality (22) 22
lung neoplasms - pathology (21) 21
chemotherapy (20) 20
cisplatin - administration & dosage (20) 20
gefitinib (20) 20
carcinoma, non-small-cell lung - mortality (19) 19
carcinoma, non-small-cell lung - pathology (19) 19
aged, 80 and over (17) 17
neoplasm staging (16) 16
disease-free survival (15) 15
survival rate (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
cisplatin (14) 14
lung cancer, non-small cell (14) 14
thailand (14) 14
cancer (13) 13
survival analysis (13) 13
respiratory system (12) 12
survival (12) 12
antineoplastic agents - therapeutic use (11) 11
deoxycytidine - analogs & derivatives (11) 11
docetaxel (11) 11
hematology, oncology and palliative medicine (11) 11
non-small cell lung cancer (11) 11
therapy (11) 11
care and treatment (10) 10
deoxycytidine - administration & dosage (10) 10
drug administration schedule (10) 10
erlotinib (10) 10
gemcitabine (10) 10
lung neoplasms - genetics (10) 10
quality of life (10) 10
trial (10) 10
analysis (9) 9
asia (9) 9
carboplatin - administration & dosage (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
lung cancer (9) 9
paclitaxel - administration & dosage (9) 9
prospective studies (9) 9
protein kinase inhibitors - therapeutic use (9) 9
quinazolines - therapeutic use (9) 9
nsclc (8) 8
open-label (8) 8
receptor, epidermal growth factor - genetics (8) 8
adenocarcinoma (7) 7
antineoplastic agents - adverse effects (7) 7
double-blind method (7) 7
erlotinib hydrochloride (7) 7
non-small-cell lung cancer (7) 7
prognosis (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
adolescent (6) 6
cell lung-cancer (6) 6
disease progression (6) 6
follow-up studies (6) 6
infusions, intravenous (6) 6
kaplan-meier estimate (6) 6
medicine, general & internal (6) 6
mutation (6) 6
proportional hazards models (6) 6
quinazolines - administration & dosage (6) 6
adenocarcinoma - drug therapy (5) 5
adenocarcinoma - pathology (5) 5
carboplatin (5) 5
carcinoma, small cell - drug therapy (5) 5
cisplatin - adverse effects (5) 5
egfr (5) 5
etoposide - administration & dosage (5) 5
ifosfamide - administration & dosage (5) 5
multicenter (5) 5
phase-iii trial (5) 5
quinazolines - adverse effects (5) 5
1st-line treatment (4) 4
adenocarcinoma - genetics (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
asian continental ancestry group (4) 4
cholangiocarcinoma (4) 4
clinical trials (4) 4
dose-response relationship, drug (4) 4
egfr mutations (4) 4
epidermal growth factor (4) 4
epirubicin - administration & dosage (4) 4
genetic aspects (4) 4
inhibitor (4) 4
medical colleges (4) 4
pemetrexed (4) 4
pulmonary and respiratory medicine (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text MTE16.01 Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy
by Thongprasert, S
Journal of Thoracic Oncology, ISSN 1556-0864, 10/2018, Volume 13, Issue 10, pp. S220 - S220
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text MS 07.06 Which Chemotherapy or Targeted Therapy is Better for Treatment of LCNEC Patients: SCLC-based versus Non-SCLC-based Regimens?
by Thongprasert, S
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2017, Volume 12, Issue 11, pp. S1686 - S1686
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text SC29.05 The Thai Experience to Overcome High Cost Drug in Cancer
by Thongprasert, Sumitra
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S143 - S144
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The role of chemotherapy in cholangiocarcinoma
by Thongprasert, S
Annals of Oncology, ISSN 0923-7534, 2005, Volume 16, Issue 2, pp. ii93 - ii96
ADJUVANT CHEMOTHERAPY | PHASE-II TRIAL | ONCOLOGY | 1ST-LINE CHEMOTHERAPY | MITOMYCIN-C | GALLBLADDER CARCINOMA | TREE CARCINOMAS | 5-FU ECF | GEMCITABINE | ADVANCED BILIARY-TRACT | LEVOFOLINIC ACID | Fluorouracil - therapeutic use | Leucovorin - administration & dosage | Antimetabolites, Antineoplastic - therapeutic use | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Deoxycytidine - administration & dosage | Humans | Deoxycytidine - analogs & derivatives | Antimetabolites, Antineoplastic - administration & dosage | Cisplatin - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
by Wu, Yi-Long, Prof and Lee, Jin Soo, MD and Thongprasert, Sumitra, MD and Yu, Chong-Jen, Prof and Zhang, Li, Prof and Ladrera, Guia, MD and Srimuninnimit, Vichien, MD and Sriuranpong, Virote, MD and Sandoval-Tan, Jennifer, MD and Zhu, Yunzhong, Prof and Liao, Meilin, Prof and Zhou, Caicun, MD and Pan, Hongming, MD and Lee, Victor, FRCR and Chen, Yuh-Min, PhD and Sun, Yan, MD and Margono, Benjamin, PhD and Fuerte, Fatima, MD and Chang, Gee-Chen, MD and Seetalarom, Kasan, MD and Wang, Jie, Prof and Cheng, Ashley, MBBS and Syahruddin, Elisna, PhD and Qian, Xiaoping, MD and Ho, James, MD and Kurnianda, Johan, SPPD and Liu, Hsingjin Eugene, MD and Jin, Kate, MD and Truman, Matt, MSc and Bara, Ilze, MD and Mok, Tony, Prof
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 777 - 786
Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly... 
Hematology, Oncology and Palliative Medicine | PHASE-III TRIAL | CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | GEFITINIB | MULTICENTER | THERAPY | NSCLC | ONCOLOGY | ADENOCARCINOMA | OPEN-LABEL | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Double-Blind Method | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Treatment Outcome | Chi-Square Distribution | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Care and treatment | Chemotherapy | Clinical trials | Lung cancer, Non-small cell | Antineoplastic agents | Tumors | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
by Mok, Tony S and Wu, Yi-Long and Thongprasert, Sumitra and Yang, Jin-Ji and Yang, Chih-Hsin and Chu, Da-Tong and Saijo, Nagahiro and Sunpaweravong, Patrapim and Han, Baohui and Margono, Benjamin and Ichinose, Yukito and Nishiwaki, Yutaka and Ohe, Yuichiro and Chewaskulyong, Busyamas and Jiang, Haiyi and Duffield, Emma L and Watkins, Claire L and Armour, Alison A and Fukuoka, Masahiro
The New England Journal of Medicine, ISSN 0028-4793, 09/2009, Volume 361, Issue 10, pp. 947 - 957
This trial compared gefitinib, an inhibitor of the tyrosine kinase of epidermal growth factor (EGFR), with carboplatin plus paclitaxel as initial treatment of... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | FACTOR-RECEPTOR GENE | MULTICENTER | THERAPY | FUNCTIONAL ASSESSMENT | PROSPECTIVE PHASE-II | 1ST-LINE GEFITINIB | EGFR MUTATIONS | TREATED PATIENTS | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Carboplatin - adverse effects | Carboplatin - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Adenocarcinoma - drug therapy | Paclitaxel - therapeutic use | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Adenocarcinoma - mortality | Care and treatment | Dosage and administration | Nonsmokers | Gefitinib | Health aspects | Lung cancer | Chemotherapy | Pharmaceutical industry | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
by Shukui Qin and Yuxian Bai and Ho Yeong Lim and Sumitra Thongprasert and Yee Chao and Jia Fan and Tsai-Shen Yang and Vajarabhongsa Bhudhisawasdi and Won Ki Kang and Yu Zhou and Jee Hyun Lee and Yan Sun
Journal of Clinical Oncology, ISSN 0732-183X, 10/2013, Volume 31, Issue 28, pp. 3501 - 3508
Purpose To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced... 
PHASE-II | ONCOLOGY | HEPATITIS-B | SORAFENIB | SYSTEMIC THERAPY | Leucovorin - administration & dosage | Carcinoma, Hepatocellular - mortality | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Palliative Care | Liver Neoplasms - mortality | Young Adult | Organoplatinum Compounds - administration & dosage | Carcinoma, Hepatocellular - drug therapy | Fluorouracil - administration & dosage | Adult | Female | Liver Neoplasms - pathology | Doxorubicin - administration & dosage | Liver Neoplasms - drug therapy | Survival Rate | International Agencies | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
by Masahiro Fukuoka and Yi-Long Wu and Sumitra Thongprasert and Patrapim Sunpaweravong and Swan-Swan Leong and Virote Sriuranpong and Tsu-Yi Chao and Kazuhiko Nakagawa and Da-Tong Chu and Nagahiro Saijo and Emma L. Duffield and Yuri Rukazenkov and Georgina Speake and Haiyi Jiang and Alison A. Armour and Ka-Fai To and James Chih-Hsin Yang and Tony S.K. Mok
Journal of Clinical Oncology, ISSN 0732-183X, 07/2011, Volume 29, Issue 21, pp. 2866 - 2874
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and carboplatin/paclitaxel in previously untreated never-smokers and light... 
TRIAL | CHEMOTHERAPY-NAIVE PATIENTS | FACTOR-RECEPTOR GENE | PLACEBO | ONCOLOGY-GROUP | ONCOLOGY | TYROSINE KINASE | SENSITIVITY | EGFR MUTATIONS | MOLECULAR PREDICTORS | PREVIOUSLY TREATED PATIENTS | Immunohistochemistry | Lung Neoplasms - drug therapy | Predictive Value of Tests | Adenocarcinoma - pathology | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Time Factors | Gefitinib | Odds Ratio | Paclitaxel - administration & dosage | Adenocarcinoma - chemistry | Precision Medicine | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - chemistry | Risk Assessment | Risk Factors | Carboplatin - administration & dosage | In Situ Hybridization, Fluorescence | Logistic Models | Survival Rate | Adenocarcinoma - drug therapy | Biomarkers, Tumor - genetics | Mutation | Carcinoma, Non-Small-Cell Lung - chemistry | Adenocarcinoma of Lung | ErbB Receptors - genetics | Lung Neoplasms - pathology | Patient Selection | Female | Adenocarcinoma - genetics | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Gene Dosage | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | ErbB Receptors - analysis | Adenocarcinoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
by Shepherd, Frances A and Rodrigues Pereira, José and Ciuleanu, Tudor and Tan, Eng Huat and Hirsh, Vera and Thongprasert, Sumitra and Campos, Daniel and Maoleekoonpiroj, Savitree and Smylie, Michael and Martins, Renato and van Kooten, Maximiliano and Dediu, Mircea and Findlay, Brian and Tu, Dongsheng and Johnston, Dianne and Bezjak, Andrea and Clark, Gary and Santabárbara, Pedro and Seymour, Lesley and Natl Canc Inst Canada Clin Trials and National Cancer Institute of Canada Clinical Trials Group
The New England Journal of Medicine, ISSN 0028-4793, 07/2005, Volume 353, Issue 2, pp. 123 - 132
The efficacy of erlotinib in patients with non–small-cell lung cancer and relapse after treatment with conventional chemotherapy was tested in a... 
PHASE-III TRIAL | SURVIVAL | GROWTH-FACTOR RECEPTOR | MEDICINE, GENERAL & INTERNAL | GEFITINIB | RESPONSIVENESS | CHEMOTHERAPY REGIMENS | PLATINUM | RANDOMIZED-TRIAL | MUTATIONS | DOCETAXEL | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Double-Blind Method | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Cisplatin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Survival Analysis | Aged, 80 and over | Quality of Life | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Clinical trials | Lung cancer, Non-small cell | Care and treatment | Chemotherapy | Inhibitor drugs | Lung cancer | Medical treatment
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
by Shi, Yuankai and Au, Joseph Siu-Kie and Thongprasert, Sumitra and Srinivasan, Sankar and Tsai, Chun-Ming and Khoa, Mai Trong and Heeroma, Karin and Itoh, Yohji and Cornelio, Gerardo and Yang, Pan-Chyr
Journal of Thoracic Oncology, ISSN 1556-0864, 02/2014, Volume 9, Issue 2, pp. 154 - 162
PIONEER (NCT01185314) was a prospective, multinational, epidemiological study of epidermal growth factor receptor ( ) mutations in patients from Asia with... 
Adenocarcinoma | epidemiology | Non–small-cell lung cancer | Epidermal growth factor receptor mutation | Asian | SURVIVAL | 1ST-LINE TREATMENT | DIAGNOSIS | GEFITINIB | Non-small-cell lung cancer | FOLLOW-UP | OPEN-LABEL | CHEMOTHERAPY | CLINICAL-PRACTICE GUIDELINES | ONCOLOGY | RESPIRATORY SYSTEM | FACTOR RECEPTOR MUTATIONS | INTERNATIONAL-ASSOCIATION | Receptor, Epidermal Growth Factor - genetics | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Lung Neoplasms - pathology | Male | Adenocarcinoma, Bronchiolo-Alveolar - genetics | Young Adult | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Adenocarcinoma - genetics | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Mutation - genetics | Adenocarcinoma - secondary | Adenocarcinoma, Bronchiolo-Alveolar - secondary | Asia - epidemiology | Molecular Epidemiology | Adolescent | Aged | Neoplasm Staging | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
by Ronald B. Natale and Sumitra Thongprasert and F. Anthony Greco and Michael Thomas and Chun-Ming Tsai and Patrapim Sunpaweravong and David Ferry and Clive Mulatero and Robert Whorf and Joyce Thompson and Fabrice Barlesi and Peter Langmuir and Sven Gogov and Jacqui A. Rowbottom and Glenwood D. Goss
Journal of Clinical Oncology, ISSN 0732-183X, 03/2011, Volume 29, Issue 8, pp. 1059 - 1066
Purpose Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. This phase III... 
GEFITINIB | MALIGNANT-TUMORS | CHEMOTHERAPY REGIMENS | ONCOLOGY | TYROSINE KINASE | CLINICAL-TRIALS | RANDOMIZED-TRIAL | JAPANESE PATIENTS | INHIBITOR | DOCETAXEL | ZD6474 | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | North America | Time Factors | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Double-Blind Method | Risk Assessment | Europe | Risk Factors | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Asia | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Piperidines - adverse effects | Quinazolines - adverse effects | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Abnormal performance of cervical stabilizer muscles in individuals with low back pain
by Thongprasert, Chattrachoo and Kanlayanaphotporn, R
Journal of Manual & Manipulative Therapy, ISSN 1066-9817, 08/2019, Volume 27, Issue 4, pp. 215 - 221
Objectives: To compare the performance of cervical stabilizer muscles using the craniocervical flexion test (CCFT) among individuals with subacute, chronic,... 
craniocervical flexion test | low back pain | Core stabilizer muscles | lumbar spine | spinal stability | deep neck muscles | motor control | Cervical spine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
by Giorgio V. Scagliotti and Maciej Krzakowski and Aleksandra Szczesna and Janos Strausz and Anatoly Makhson and Martin Reck and Rafal F. Wierzbicki and Istvan Albert and Michael Thomas and Jose Elias Abrao Miziara and Zsolt S. Papai and Nina Karaseva and Sumitra Thongprasert and Elsa Dalmau Portulas and Joachim von Pawel and Ke Zhang and Paulina Selaru and Lesley Tye and Richard C. Chao and Ramaswamy Govindan
Journal of Clinical Oncology, ISSN 0732-183X, 06/2012, Volume 30, Issue 17, pp. 2070 - 2078
Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non-small-cell lung cancer (NSCLC), based on the importance... 
SURVIVAL | TYROSINE KINASE INHIBITOR | MULTICENTER | ONCOLOGY | SU11248 | PROGRESSION | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Double-Blind Method | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Indoles - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrroles - administration & dosage | Aged, 80 and over | Placebos | Adult | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Smoking | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Crizotinib treatment for advanced non-small-cell lung cancer patients: a budget impact analysis based in Thailand
by Thongprasert, Sumitra and Permsuwan, Unchalee
Current Medical Research and Opinion, ISSN 0300-7995, 05/2017, Volume 33, Issue 5, pp. 955 - 961
Objective: With the advent of the anaplastic lymphoma kinase (ALK) inhibitor, treatment of ALK-positive advanced non-small-cell lung cancer (NSCLC) patients... 
crizotinib | cost | Budget impact analysis | Thailand | non-small-cell lung cancer | MEDICINE, RESEARCH & EXPERIMENTAL | CARBOPLATIN | PHASE-III | REARRANGEMENTS | CHEMOTHERAPY | TRIAL | TABLETS | MEDICINE, GENERAL & INTERNAL | ERLOTINIB | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Humans | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Pyridines - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Dietary iron intake and availability are related to maternal education level in overweight/obese adolescents
by Thongprasert, Chaleelak and Thongprasert, Chaleelak and Hutchinson, Carol and Hutchinson, Carol and Satheannoppakao, Warapone and Satheannoppakao, Warapone and Tipayamongkholgul, Mathuros and Tipayamongkholgul, Mathuros
European Journal of Nutrition, ISSN 1436-6207, 9/2018, Volume 57, Issue 6, pp. 2249 - 2260
To compare intakes of dietary iron and enhancers and inhibitors of iron absorption between overweight/obese (OW/OB) adolescents and their normal weight (NW)... 
Overweight/obese | Chemistry | Nutrition | Enhancer | Parental education | Adolescent | Iron | Inhibitor | HEALTHY GROWTH | NONHEME IRON | DOUBLE BURDEN | DEFICIENCY | CHILDREN | OMNIVOROUS DIETS | OBESITY | NUTRITION & DIETETICS | INFLAMMATION | CONSUMING VEGETARIAN | ASSOCIATION | Body Mass Index | Iron, Dietary - pharmacokinetics | Prospective Studies | Cross-Sectional Studies | Humans | Male